Previous studies have shown that ectopic expression of miR-195 also sensitized glioblastoma, hepatocellular carcinoma, breast cancer, and colon tumor cells to temozolomide, 5-fluorouracil, adriamycin, and doxorubicin treatment by targeting BCL2L-2, BCL-W, and RAF-1 genes, respectively [23, 43–45]. The gene discussed is BCL2L2; the disease is breast carcinoma.